Genetics of Detoxification
Detoxification pathways process and eliminate drugs, environmental toxins, and endogenous metabolites. Genetic variants in cytochrome P450 enzymes, Phase II conjugation enzymes, and transport proteins influence detoxification capacity and medication sensitivity.
This page is for educational and informational purposes only. Not a diagnostic tool. Always consult a qualified healthcare provider.
What is Detoxification?
The body's detoxification system is primarily housed in the liver and involves three phases: Phase I oxidation (mainly cytochrome P450 enzymes), Phase II conjugation (glutathione transferases, UGTs, sulfotransferases), and Phase III transport (ABC transporters, OATPs). Genetic variation in these enzymes underlies most pharmacogenomic differences between individuals — influencing drug metabolism rates, toxin susceptibility, and endogenous metabolite clearance. In the context of chronic illness, impaired detoxification capacity may contribute to chemical sensitivity, medication side effects, and accumulation of inflammatory metabolites.
Biological pathways commonly discussed in relation to Detoxification
Research into Detoxification and Xenobiotic Metabolism has highlighted several biological pathways that may be relevant. Genetic variants within these pathways may influence individual susceptibility, symptom severity, or the trajectory of the condition.
Cyp450 Phase1
Cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP2C9, CYP3A4) perform oxidative biotransformation of drugs and toxins. Variants create poor, intermediate, extensive, and ultra-rapid metaboliser phenotypes.
Phase2 Conjugation
Phase II enzymes including GSTs, UGT1A1, NAT2, SULT1A1, and FMO3 conjugate Phase I metabolites for excretion. Variants may reduce conjugation efficiency, increasing exposure to reactive intermediates.
Phase3 Transport
ABC transporters (ABCB1, ABCG2) and OATPs (SLCO1B1) control cellular drug uptake and efflux. Variants may alter drug distribution and tissue exposure.
Glutathione Pathway
Glutathione is central to Phase II detoxification and antioxidant defence. GSTM1 and GSTT1 null genotypes reduce glutathione conjugation capacity for many environmental toxins.
Key genes studied in relation to Detoxification
The following genes have been studied in relation to Detoxification and Xenobiotic Metabolism. These genes span the biological pathways most commonly discussed in this area of research.
23 genes total studied in relation to Detoxification across the ChronicDNA dataset.
Genetic variants commonly discussed
The following genetic variants (SNPs) are found in genes that have been studied in relation to Detoxification. Each variant represents a position in the genome where individuals may carry different alleles.
61 variants total across genes studied in relation to Detoxification.
How personal DNA data may provide educational insights
Consumer DNA files from 23andMe, AncestryDNA, and MyHeritage contain raw SNP data. When you upload your file to ChronicDNA, the analysis engine checks your genotype against a curated panel of 80+ genes selected for their relevance to Long COVID, ME/CFS, and connected biological pathways - some of which may relate to areas such as Detoxification.
This is not a diagnostic service. Genetic variants do not determine whether you have Detoxification, nor do they predict your clinical outcomes. The report is educational - it explains which variants you carry, what the research says about them, and how they fit into the biological pathways most relevant to chronic illness. All results should be discussed with a qualified healthcare provider.
Related conditions and pathways
Detoxification shares biological pathways and genetic associations with the following related conditions and areas of research.
Frequently asked questions
What is detoxification in genetic terms?
Detoxification refers to the enzymatic processes — primarily in the liver — that convert drugs, environmental chemicals, and endogenous metabolites into water-soluble forms for excretion. Genetic variants in Phase I (CYP450), Phase II (GST, UGT, NAT2), and Phase III (ABC transporters) enzymes influence individual detoxification capacity.
How may detoxification genetics relate to chronic illness?
In conditions like ME/CFS and Long COVID, some patients report chemical sensitivity and medication intolerance. Variants reducing Phase I or Phase II detoxification capacity may result in higher tissue exposure to reactive metabolites, potentially contributing to symptoms.
Which detoxification genes are most clinically relevant?
The most clinically studied pharmacogenomic genes are CYP2D6, CYP2C19, CYP2C9, VKORC1, SLCO1B1, and DPYD — these influence metabolism of many common medications. Additionally, GSTM1, GSTT1, and NQO1 are relevant to environmental toxin handling.
What does it mean to be a poor metaboliser?
A poor metaboliser carries two loss-of-function variants in a CYP450 gene, significantly reducing enzyme activity. This can result in slower drug clearance, higher plasma drug levels, and increased risk of side effects for medications metabolised by that enzyme.
Explore DNA insights
If you already have DNA data from 23andMe, AncestryDNA, or MyHeritage, upload your raw file to ChronicDNA and receive a personalised educational report covering genes studied in relation to Detoxification and connected biological pathways.
Get Your Personalised DNA ReportInformational and educational only · Not a diagnostic tool · GDPR compliant
23 genes · 61 variants analysed in relation to Detoxification